# Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

> **NCT06463444** · PHASE1 · RECRUITING · sponsor: **Chen Xiaoping** · enrollment: 30 (estimated)

## Conditions studied

- HCC
- Precision Therapy

## Interventions

- **DRUG:** HAIC + Tislelizumab +lenvatinib

## Key facts

- **NCT ID:** NCT06463444
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463444, "Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06463444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*